SCHEMBL2384971

SCHEMBL2384971

CC(=O)c1ccc(N2CCN(c3nsnc3OCc3ccncc3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
HSD17B10 Q99714 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
HRH3 Q9Y5N1 4/20 0.48
HRH4 Q9H3N8 1/20 0.45
MAPT P10636 7/20 0.43
GRM5 P41594 1/20 0.42
KMT2A Q03164 4/20 0.42
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 2/20 0.41
MEN1 O00255 2/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
MLLT1 Q03111 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383819 0.84 ALDH1A1 (0.67) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL5572377 0.81 ALDH1A1 (0.56) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL2383667 0.78 ALDH1A1 (0.57) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL2384061 0.78 GPR119 (0.63) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL2384241 0.77 ALDH1A1 (0.54) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL2382669 0.76 ALDH1A1 (0.57) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL2385264 0.75 GPR119 (0.59) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL7956272 0.74 NPC1 (0.69) ALDH1A1TSHRNPC1RAB9AHRH3
SCHEMBL2385630 0.74 ALDH1A1 (0.49) ALDH1A1ALOX15TSHRMAPK1HSD17B10
SCHEMBL2386623 0.74 ALDH1A1 (0.50) ALDH1A1ALOX15TSHRMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
EP-1608373-A2 TIE-2 MODULATORS AND METHODS OF USE Exelixis Inc. (US) 2005-12-28 EP disclosed
WO-2004083235-A2 TIE-2 MODULATORS AND METHODS OF USE EXELIXIS INC. (US) 2004-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR ALDH1A1 3053/4885ALOX15 1554/4885TSHR 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.